Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter StudyJingwen Ai, Ci Qu, Jing Liang et al.|Clinical Gastroenterology and Hepatology|2021Cited by 73
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter studyJitao Wang, Zhongwei Zhao, Qiran Zhang et al.|Hepatology International|2022Cited by 32
Safety and immunogenicity of COVID‐19 vaccination in patients with hepatocellular carcinoma (CHESS‐NMCID 2101): A multicenter prospective studyXiaolong Qi, Wenhong Zhang, Jitao Wang et al.|Journal of Medical Virology|2022Cited by 12
Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter studyJitao Wang, Zhongwei Zhao, Qiran Zhang et al.|Hepatology International|2023Cited by 5
Immunogenicity and safety of a booster COVID‐19 vaccination in patients with chronic liver disease: A multicenter studyJitao Wang, Wenhong Zhang, Jingwen Ai et al.|Portal hypertension & cirrhosis|2023Cited by 0